SEP 24, 2014 05:00 AM PDT

Algorithmic Drug Design (Prerecorded)

28 42 1714

  • Chair of Medicinal Informatics and Professor of Translational Biology, University of Dundee
      Andrew attended the University of Manchester on a British Steel Scholarship, graduating with a First Class Honours in Chemistry. Following a spell in the steel industry, Andrew undertook a doctorate in molecular biophysics under at the University of Oxford under the supervision of Prof David Stuart FRS. Directly from Oxford he joined Pfizer in 1998, where he established various new functions for the company including the Target Analysis Group, Indications Discovery and Knowledge Discovery. He has won several awards including the Royal Society of Chemistry's Capps Green Zomaya medal (2008); Corwin Hansch Award (2007); Pfizer Team Achievement Award (2004); Pfizer Achievement Award (2002); Pfizer Leadership Award (2002). Andrew's papers include the highest cited paper published in the past 5 years by Nature Chemical Biology and the second highest cited paper ever published by Nature Reviews Drug Discovery.

    Since leaving Pfizer to go back to academia in 2007, Andrew Hopkins (University of Dundee, UK) has been a leading researcher in the search for new informatics and computational methods to improve the design of effective drug candidates against G-protein coupled receptors and other prominent drug classes. In this presentation, Hopkins reviews his groups latest progress using Bayesian approaches for Algorithmic Drug Design, which show immense promise for the identification of new classes of small molecule drug compounds.

    Show Resources
    Loading Comments...